The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

Mergers & AcquisitionsMediumUpdated•Originally published 12 May 2026•Updated 13 May 2026•

1 min read

Bristol-Myers Squibb Inks $15 Billion Strategic Deal with Hengrui Pharma

Illustration of a pipeline connecting Bristol-Myers Squibb and Hengrui Pharma logos with a $15 billion block.

Key Facts

1U.S. pharmaceutical giant Bristol-Myers Squibb has struck a strategic partnership and licensing deal with major Chinese drugmaker Hengrui Pharmaceuticals.

21 days ago

Version History

Version 121 days ago

U.S. pharmaceutical giant Bristol-Myers Squibb has struck a strategic partnership and licensing deal with major Chinese drugmaker Hengrui Pharmaceuticals. According to reports, the deal could be worth more than $15 billion in total value. This collaboration marks a significant move to leverage strategic opportunities between the two major pharmaceutical entities.

This agreement comes as the global pharma sector seeks to diversify pipelines and tap into Asian innovation, following similar expansion patterns seen by peers like Merck and Pfizer. Compared to previous quarters, such mega-cap licensing deals signal continued growth in cross-border biotech investments. Per market data, the $15 billion valuation represents one of the largest strategic alliances in the sector recently.

Investors are monitoring BMY stock performance following the announcement. Looking ahead to the economic calendar, the market awaits U.S. Initial Jobless Claims on May 7, 2026, which may impact broader equity sentiment. Key catalysts to watch include regulatory filings and milestone updates related to the partnership's drug development phases.